The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1511
January 2, 2017
View Complete Issue         Table of Contents 2019 
Tenofovir Alafenamide (Vemlidy) for Hepatitis B
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tenofovir Alafenamide (Vemlidy) for Hepatitis B
January 2, 2017 (Issue: 1511)
The FDA has approved tenofovir alafenamide (Vemlidy – Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first single-drug product containing tenofovir alafenamide (TAF), a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tenofovir Alafenamide (Vemlidy) for Hepatitis B
Article code: 1511d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.